The Cystic Fibrosis Core Center at Case Western Reserve University proposes to continue to pursue its goal of the conquest of cystic fibrosis. In order to achieve that goal, a multidisciplinary program ranging from studies of the molecular biology of CFTR to therapeutic trials in patients with CF is in place. Over 30 investigators from six departments receive over $6 million per year in direct support of CF- related projects. This highly interactive group of investigators depends on five cores supported by the CF Core Center: the Administrative Core, which now includes the Statistical Facility; the Epithelial Cell Culture Core which provides facilities, expertise, and cost savings for investigators using tissue culture; the Cell Physiology Core, which provides electrophysiology and videomicroscopy equipment Center investigators as well as instruction in their use; the Morphology Core, which provides access to expertise and instrumentation for electron microscopy and fluorescence light microscopy and Nomarski optic, as well as histopathology services; and the Inflammatory Mediator/BAL Core which provide samples of CF, normal, and disease control bronchoalveolar lavage fluid to investigators, as well as cost savings on assays of cytokines, eicosanoids, and intracellular signalling molecules. Besides these Cores, the Center proposes to support two feasibility projects at a time, which will allow new investigators to work on CF-related ideas, investigators established in another area to turn attention to CF, and CF investigators to try out entirely novel concepts. In the last five year period, the Center has thrived and developed active research programs in CF gene therapy, CFTR channel physiology, activation of CFTR mutants, CFTR processing, and inflammation in the CF lung. We have completed a trial of an antiinflammatory agent which reduced the rate of decline of CF lung function substantially over the four year period of the study, and is now coming into wide clinical use. Continuation of the cross-fertilization of the clinical work with the basic science will surely bring us closer to our goal of controlling CF in the next five year period, as it clearly has in the current grant period.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK027651-18
Application #
6177304
Study Section
Special Emphasis Panel (SRC (01))
Program Officer
Mckeon, Catherine T
Project Start
1983-01-01
Project End
2001-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
18
Fiscal Year
2000
Total Cost
$1,143,880
Indirect Cost
Name
Case Western Reserve University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Lai, Nicola; M Kummitha, China; Rosca, Mariana G et al. (2018) Isolation of mitochondrial subpopulations from skeletal muscle: Optimizing recovery and preserving integrity. Acta Physiol (Oxf) :e13182
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
Darrah, Rebecca; Nelson, Rebecca; Damato, Elizabeth G et al. (2016) Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biol Res Nurs 18:498-504
VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9
VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790
Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42
Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Rymut, Sharon M; Kampman, Claire M; Corey, Deborah A et al. (2016) Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 311:L317-27
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87

Showing the most recent 10 out of 445 publications